These findings have significant therapeutic implications, suggesting that liver-selective downregulation of ChREBP could protect against systemic insulin resistance that frequently develops early in the pathogenesis of NAFLD and T2DM. This evidence concerns the gene MLXIPL and metabolic dysfunction-associated steatotic liver disease.